Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

BACKGROUND: Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia. Prophylactic use of recombinant human G-CSF such as daily filgrastim and once-per-cycle pegfilgrastim may reduce the incidence of febrile neutropenia. This comparative study examined the effect of pegfilgrastim...

Descripción completa

Detalles Bibliográficos
Autores principales: Naeim, Arash, Henk, Henry J, Becker, Laura, Chia, Victoria, Badre, Sejal, Li, Xiaoyan, Deeter, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559272/
https://www.ncbi.nlm.nih.gov/pubmed/23298389
http://dx.doi.org/10.1186/1471-2407-13-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559272/
https://www.ncbi.nlm.nih.gov/pubmed/23298389
http://dx.doi.org/10.1186/1471-2407-13-11

Ejemplares similares